PT  - JOURNAL ARTICLE
AU  - Jeffrey R.  Curtis
AU  - Fenglong Xie
AU  - Shuo Yang
AU  - Maria I.  Danila
AU  - Justin K.  Owensby
AU  - Lang Chen
TI  - Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States
AID  - 10.3899/jrheum.180071
DP  - 2018 Nov 15
TA  - The Journal of Rheumatology
PG  - jrheum.180071
4099  - http://www.jrheum.org/content/early/2018/11/12/jrheum.180071.short
4100  - http://www.jrheum.org/content/early/2018/11/12/jrheum.180071.full
AB  - Objective The clinical utility of the multibiomarker disease activity (MBDA) test for rheumatoid arthritis (RA) management in routine care in the United States has not been thoroughly studied. Methods Using 2011–2015 Medicare data, we linked each patient with RA to their MBDA test result. Initiation of a biologic or Janus kinase (JAK) inhibitor in the 6 months following MBDA testing was described. Multivariable adjustment evaluated the likelihood of adding or switching biologic/JAK inhibitor, controlling for potential confounders. For patients with high MBDA scores who added a new RA therapy and were subsequently retested, lack of improvement in the MBDA score was evaluated as a predictor of future RA medication failure, defined by the necessity to change RA medications again. Results Among 60,596 RA patients with MBDA testing, the proportion adding or switching biologics/JAK inhibitor among those not already taking a biologic/JAK inhibitor was 9.0% (low MBDA), 11.8% (moderate MBDA), and 19.7% (high MBDA, p < 0.0001). Similarly, among those already taking biologics/JAK inhibitor, the proportions were 5.2%, 8.3%, and 13.5% (p < 0.0001). After multivariable adjustment, referent to those with low disease MBDA scores, the likelihood of switching was 1.51-fold greater (95% CI 1.35–1.69) for patients with moderate MBDA scores, and 2.62 (2.26–3.05) for patients with high MBDA scores. Among those with high MBDA scores who subsequently added a biologic/JAK inhibitor and were retested, lack of improvement in the MBDA score category was associated with likelihood of future RA treatment failure (OR 1.61, 95% CI 1.27–2.03). Conclusion The MBDA score was associated with both biologic and JAK inhibitor medication addition/switching and subsequent treatment outcomes.